| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/17/2023 | 326.83% | Piper Sandler | $3 → $7 | Maintains | Overweight |
| 01/06/2023 | 82.93% | Piper Sandler | $2 → $3 | Upgrades | Neutral → Overweight |
| 01/06/2023 | 82.93% | Jefferies | $2.5 → $3 | Upgrades | Hold → Buy |
| 11/03/2022 | 21.95% | SVB Leerink | $3 → $2 | Maintains | Market Perform |
| 05/05/2022 | 82.93% | SVB Leerink | $7 → $3 | Downgrades | Outperform → Market Perform |
| 03/23/2022 | 326.83% | SVB Leerink | $11 → $7 | Maintains | Outperform |
| 03/23/2022 | 143.9% | Piper Sandler | $15 → $4 | Downgrades | Overweight → Neutral |
| 03/11/2022 | 814.63% | Piper Sandler | $47 → $15 | Maintains | Overweight |
| 03/11/2022 | 570.73% | SVB Leerink | $10 → $11 | Maintains | Outperform |
| 02/16/2022 | 509.76% | SVB Leerink | $15 → $10 | Maintains | Outperform |
| 01/07/2022 | 631.71% | JP Morgan | $30 → $12 | Downgrades | Overweight → Neutral |
| 01/07/2022 | 814.63% | SVB Leerink | $29 → $15 | Maintains | Outperform |
| 09/09/2021 | 1668.29% | SVB Leerink | → $29 | Initiates Coverage On | → Outperform |
| 11/10/2020 | 1485.37% | Jefferies | → $26 | Initiates Coverage On | → Buy |
| 11/10/2020 | 1912.2% | JP Morgan | → $33 | Initiates Coverage On | → Overweight |
| 11/10/2020 | 2034.15% | Piper Sandler | → $35 | Initiates Coverage On | → Overweight |
What is the target price for Aligos Therapeutics (ALGS)?
The latest price target for Aligos Therapeutics (NASDAQ: ALGS) was reported by Piper Sandler on January 17, 2023. The analyst firm set a price target for $7.00 expecting ALGS to rise to within 12 months (a possible 326.83% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aligos Therapeutics (ALGS)?
The latest analyst rating for Aligos Therapeutics (NASDAQ: ALGS) was provided by Piper Sandler, and Aligos Therapeutics maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Aligos Therapeutics (ALGS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aligos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aligos Therapeutics was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.
Is the Analyst Rating Aligos Therapeutics (ALGS) correct?
While ratings are subjective and will change, the latest Aligos Therapeutics (ALGS) rating was a maintained with a price target of $3.00 to $7.00. The current price Aligos Therapeutics (ALGS) is trading at is $1.64, which is out of the analyst's predicted range.